Vital Therapies reports Phase III trial of VTI-208 reaches enrollment target
"Executing on VTI-208 has been our primary focus over the last two years at about 50 leading hospitals in the U.S., Europe and Australia," said Terry Winters, Ph.D.,
The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have granted paediatric clinical trial waivers to Shanton Pharma for its lead candidate SAP-001, easing the drug’s regulatory paths to approval.
Compared to other anti-inflammatory drugs available such as biologics, steroids and non-steroidal anti-inflammatory drugs, Anatabine Citrate has a distinct anti-inflammatory mode of action. The three-part Phase I trial
MOXIe (A two-part, randomized, placebo-controlled Phase 2/3 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich’s Ataxia) is a multi-center study in